FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2048484328> ?p ?o ?g. }

• W2048484328 endingPage "14693" @default.
• W2048484328 startingPage "14685" @default.
• W2048484328 abstract "Endothelial nitric-oxide synthase (eNOS) is a constitutively expressed gene in endothelium that produces NO and is critical for vascular integrity. Previously, we reported that the 27-nucleotide (nt) repeat polymorphism in eNOS intron 4, a source of 27-nt small RNA, which inhibits eNOS expression, were associated with cardiovascular risk and expression of the eNOS gene. In the current study, we investigated the biogenesis of the intron 4-derived 27-nt small RNA. Using Northern blot, we showed that the eNOS-derived 27-nt short intronic repeat RNA (sir-RNA) expressed only in the eNOS expressing endothelial cells. Cells containing 10 × 27- or 5 × 27-nt repeats produced higher levels of 27nt sir-RNA and lower levels of eNOS mRNA than the cells with 4 × 27-nt repeats. The 27nt sir-RNA was mostly present within the endothelial nuclei. When the splicing junctions of the 27-nt repeat containing intron 4 in the full-length eNOS cDNA vector were mutated, 27nt sir-RNA biogenesis was abolished. Suppression of Drosha or Dicer diminished the biogenesis of the 27nt sir-RNA. Our study suggests that the 27nt sir-RNA derived through eNOS pre-mRNA splicing may represent a new class of small RNA. The more eNOS is transcribed or higher number of the 27-nt repeats, the more 27nt sir-RNA is produced, which functions as a negative feedback self-regulator by specifically inhibiting the host gene eNOS expression. This novel molecular model may be responsible for quantitative differences between individuals carrying different numbers of the polymorphic repeats hence the cardiovascular risk. Endothelial nitric-oxide synthase (eNOS) is a constitutively expressed gene in endothelium that produces NO and is critical for vascular integrity. Previously, we reported that the 27-nucleotide (nt) repeat polymorphism in eNOS intron 4, a source of 27-nt small RNA, which inhibits eNOS expression, were associated with cardiovascular risk and expression of the eNOS gene. In the current study, we investigated the biogenesis of the intron 4-derived 27-nt small RNA. Using Northern blot, we showed that the eNOS-derived 27-nt short intronic repeat RNA (sir-RNA) expressed only in the eNOS expressing endothelial cells. Cells containing 10 × 27- or 5 × 27-nt repeats produced higher levels of 27nt sir-RNA and lower levels of eNOS mRNA than the cells with 4 × 27-nt repeats. The 27nt sir-RNA was mostly present within the endothelial nuclei. When the splicing junctions of the 27-nt repeat containing intron 4 in the full-length eNOS cDNA vector were mutated, 27nt sir-RNA biogenesis was abolished. Suppression of Drosha or Dicer diminished the biogenesis of the 27nt sir-RNA. Our study suggests that the 27nt sir-RNA derived through eNOS pre-mRNA splicing may represent a new class of small RNA. The more eNOS is transcribed or higher number of the 27-nt repeats, the more 27nt sir-RNA is produced, which functions as a negative feedback self-regulator by specifically inhibiting the host gene eNOS expression. This novel molecular model may be responsible for quantitative differences between individuals carrying different numbers of the polymorphic repeats hence the cardiovascular risk. Endothelial-derived NO, mainly synthesized by endothelial nitric-oxide synthase (eNOS), 3The abbreviations used are: eNOS, endothelial nitric-oxide synthase; nt, nucleotide(s); sir-RNA, short intronic repeat small RNA; HUVEC, human umbilical vein endothelial cells; HAEC, human aortic endothelial cells; miRNA, micro-RNA; siRNA, small interfering RNA; RT, reverse transcriptase; CMV, cytomegalovirus. has a central role in maintaining the functional integrity of endothelial cells, hemodynamic regulation, arterial wall remodeling, and establishment of collateral circulation (1Gibbons G.H. Dzau V.J. N. Engl. J. Med. 1994; 330: 1431-1438Crossref PubMed Scopus (1350) Google Scholar). Effects of NO result either directly from reactions between NO and specific biological molecules through S-nitros(yl)ation (2Melino G. Bernassola F. Knight R.A. Corasaniti M.T. Nistico G. Finazzi-Agro A. Nature. 1997; 388: 432-433Crossref PubMed Scopus (375) Google Scholar), or indirectly from reactive nitrogen oxide species through oxidation (3Beckman J.S. Koppenol W.H. Am. J. Physiol. 1996; 271: C1424-C1437Crossref PubMed Google Scholar). These direct or indirect effects can produce both physiological and pathological outcomes (4Hausladen A. Stamler J.S. Methods Enzymol. 1999; 300: 389-395Crossref PubMed Scopus (70) Google Scholar). Adequate NO production is essential for anti-atherogenic and anti-thrombotic processes in the normal arterial wall; attenuated NO bioavailability promotes vascular diseases. Reduction in basal NO release may predispose to hypertension, thrombosis, vasospasm, and atherosclerosis (5Oemar B.S. Tschudi M.R. Godoy N. Brovkovich V. Malinski T. Luscher T.F. Circulation. 1998; 97: 2494-2498Crossref PubMed Scopus (356) Google Scholar), and overproduction of NO can result in excessive oxidative stress and inflammation, both of which promote vascular diseases. Central to all these physiological functions is the proper eNOS expression and adequate eNOS enzyme activity. Over recent years, tremendous research efforts have concentrated on the regulation of eNOS enzyme activities. Comparatively, progress in molecular mechanisms regulating eNOS expression at transcriptional, post-transcriptional, and translational levels is relatively slow. Although functional roles of the eNOS DNA variants are not clear, hundreds of studies investigating associations between various eNOS polymorphisms and vascular diseases have been published over the last decade. This is especially so for the 27-nucleotide (nt) repeat polymorphism in the eNOS intron 4, which is highlighted by a meta-analysis of 12,990 subjects showing significant associations with vascular diseases (6Casas J.P. Bautista L.E. Humphries S.E. Hingorani A.D. Circulation. 2004; 109: 1359-1365Crossref PubMed Scopus (280) Google Scholar). Although a recent Framingham Study reported no association between 33 single nucleotide polymorphisms in the eNOS gene and endothelial function (7Kathiresan S. Larson M.G. Vasan R.S. Guo C.Y. Vita J.A. Mitchell G.F. Keyes M.J. Newton-Cheh C. Musone S.L. Lochner A.L. Drake J.A. Levy D. O'Donnell C.J. Hirschhorn J.N. Benjamin E.J. Circulation. 2005; 112: 1419-1427Crossref PubMed Scopus (23) Google Scholar), others reported positive associations between the promoter T-786C polymorphism, CA repeats in intron 13, E298D at exon 7, and endothelial function and vascular diseases (8Wang X.L. Wang J. Mol. Genet. Metab. 2000; 70: 241-251Crossref PubMed Scopus (171) Google Scholar). Studies of ours and others suggest that the 27-nt repeat polymorphism at eNOS intron 4 is likely functional in regulating eNOS expression. Recently, we have demonstrated that: (a) the 27-nt repeats may act as an enhancer/repressor regulating eNOS expression, the effect is maintained during in vitro cell replication in endothelial cells carrying different genotypes (9Wang J. Dudley D. Wang X.L. Arterioscler. Thromb. Vasc. Biol. 2002; 22: e1-e4Crossref PubMed Google Scholar, 10Senthil D. Raveendran M. Shen Y.H. Utama B. Dudley D. Wang J. Wang X.L. DNA Cell Biol. 2005; 24: 218-224Crossref PubMed Scopus (59) Google Scholar); (b) the 27-nt repeats in eNOS intron 4 produce 27-nt small RNA, which appears to inhibit eNOS expression at the transcriptional level (11Zhang M.X. Ou H. Shen Y.H. Wang J. Coselli J. Wang X.L. Proc. Natl. Acad. Sci. U. S. A. 2005; 102: 16967-16972Crossref PubMed Scopus (107) Google Scholar, 12Ou H. Shen Y.H. Utama B. Wang J. Wang X. Coselli J. Wang X.L. Arterioscler. Thromb. Vasc. Biol. 2005; 25: 2509-2514Crossref PubMed Scopus (31) Google Scholar). However, the biogenesis of the intron 4-derived 27-nt small RNA is not clear. In the current study, we defined the molecular pathways for the 27-nt small RNA biogenesis, which is distinct from most known classes of small RNAs (13Ambros V. Nature. 2004; 431: 350-355Crossref PubMed Scopus (9087) Google Scholar, 14Zeng Y. Oncogene. 2006; 25: 6156-6162Crossref PubMed Scopus (229) Google Scholar, 15Bartel D.P. Cell. 2004; 116: 281-297Abstract Full Text Full Text PDF PubMed Scopus (29616) Google Scholar, 16Rana T.M. Nat. Rev. Mol. Cell. Biol. 2007; 8: 23-36Crossref PubMed Scopus (853) Google Scholar). This short intronic repeat small RNA (sir-RNA) could either be a new class of small RNA or an atypical form of the microRNA. We speculate that the intron 4-derived 27-nt small RNA may function as a negative feedback regulator and maintain the stable transcription of eNOS. Reagents—Restriction enzymes, T4 kinase, DNA ligases, polymerases, and other molecular biology enzymes were purchased from New England BioLabs (Beverly, MA) or Promega (Madison, WI). Plasmid and DNA gel purification kits were from Qiagen (Valencia, CA). All oligonucleotides were synthesized by iDNA Technologies, Inc. (Coralville, IA). The mirVana miRNA Isolation kit was from Ambion, Inc. (Austin, TX). Sephadex columns for probe purification were from Roche Diagnostics Corp. Anti-eNOS antibody and anti-β-actin antibodies were from Cell Signaling Technology (Beverly, MA) and Sigma. Anti-Drosha and Dicer antibodies were from Abcam Inc. (Cambridge, MA). Human tissue total RNAs were from Clontech (Mountain View, CA). Hybond nylon membrane and [32P]ATP were from GE Healthcare and PerkinElmer Life Sciences. Protein determinations were made with the Bradford method (Bio-Rad). All other chemicals were from Sigma. Plasmids—We amplified the human eNOS gene from exon 3 to intron 4 (4674 to 6498 bp) or part of intron 4 (5130 to 6430) with the standard PCR technique from genomic DNA extracted from human umbilical vein endothelial cells (HUVEC). We cloned the PCR products into pCR2.1-TOPO cloning vector (Invitrogen) re-cloned into human eNOS full-length cDNA/pCMV-2B expression vector at the ScaI site. The correct sequence and orientation of the inserts were confirmed by direct DNA sequencing. Primers with restriction enzyme site (underlined) for cloning are: sense 5′-AGTACTTACAGCTCCATTAAGAGGTGACAG-3′, antisense 5′-AGTACTCCTGAGCCAGCCGAGGCAGCGGGAGAG-3′, sense, 5′-AGTACTGGTGCGGCTGGCCAGCGACTGAGAG-3′, antisense 5′-AGTACTCCTGAGCCAGCCGAGGCAGCGGGAGAG-3′. For generation of the 10 × 27-nt construct, we carried out two separate PCR. We first amplified the DNA fragment from the 5′ end to the end of the 5th 27-nt repeat. We then amplified the DNA fragment from the beginning of the 1st 27-nt repeat to the 3′ end of the intron 4. These two DNA fragments were end-end annealed for the generation of the 10 × 27-nt fragment and inserted into the pCMV-2B-eNOS cDNA vector. For the assessment of the independent promoter, the region (1953 bp, 4545-6498 bp) spanning from eNOS exon 3 to intron 4 was amplified from HUVEC genomics DNA. Primers with KpnI and XhoI sites were: sense 5′-GGTACCCTCGACCCAGGATGGGCCCTGCACC, antisense 5′-AGATCTCCTGAGCCAGCCGAGGCAGCGGGAGAG-3′. The PCR product was cloned into pGL3 basic vector by T4 DNA ligase at XhoI and KpnI sites. In addition, the serial deletions of the 1.5-kb region upstream of the 27-nt repeats in the eNOS intron 4 were amplified by PCR before being inserted into the pGL3 basic vector at XhoI and KpnI. Site-directed mutagenesis was carried out using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) to generate the splicing-deficient constructs. siRNA-mediated Gene-specific Suppression—Following siRNA duplexes specific for Drosha and Dicer, genes were designed to suppress the expression of Drosha and Dicer. Luciferase gene-specific siRNA was used as a negative control. The target sequences for Drosha, Dicer, and luciferase were: 5′-AACCGAAGAUCACCAUCUCUG-3′, 5′-AAUCUAUUAGCACCUUGAUGU-3′, and 5′-UCGAAGUAUUCCGCGUACG-3. Before transfection with Lipofectamine 2000, formation of siRNA duplex was performed. Cell Culture and Transfection—HeLa (human cervical epithelial cancer cell line) and 293 (human embryonic renal epithelial cell line) cells were cultured in Dulbecco's modified Eagle's medium (Cellgro, Mediatech, Inc., Herndon, VA) with 10% fetal bovine serum. Human skin fibroblast cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA). Human coronary artery smooth muscle cells were purchased from Cell Application, Inc. (San Diego, CA). Human skin fibroblasts were cultured in Eagle's minimum essential medium (ATCC) with 10% fetal bovine serum. Human coronary artery smooth muscle cells were cultured in smooth muscle cell growth medium (Cell Applications, Inc.). Human aortic endothelial cells (HAEC) were obtained from Cell Application and cultured in EBM-2 endothelial cell basic medium with Bulletkit (Cambrex, Inc., Charles City, IA) containing hydrocortisone, fibroblast growth factor B, vascular endothelial growth factor, insulin-like growth factor-1, ascorbic acid, epidermal growth factor, GA-1000, heparin, and 2% fetal calf serum. Primary HUVECs were collected from human umbilical cords as described previously (10Senthil D. Raveendran M. Shen Y.H. Utama B. Dudley D. Wang J. Wang X.L. DNA Cell Biol. 2005; 24: 218-224Crossref PubMed Scopus (59) Google Scholar), which was approved by the Institutional Review Board of Baylor College of Medicine. All types of cells were cultured at 37 °C with 5% CO2. The siRNA duplex and plasmids were transfected using Lipofectamine 2000 following the manufacturer's protocol. Northern Blot and Quantitative Real-time RT-PCR—Total RNAs were extracted with TRIzol (Invitrogen) and small RNAs were isolated from the cultured cells using the mirVana miRNA Isolation kit. For Northern blots of sir-RNA, 20 μg of RNA was resolved on 15% polyacrylamide, 8 m urea gels, and electrophoresized with 130 V for 2 h at room temperature. The resolved RNAs were transferred to the positively charged Nylon membrane. The synthesized antisense 27-nt oligonucleotide probe according to the 27-nt repeat sequence in the eNOS intron 4 was 5′ end-labeled with [γ-32P]ATP by the T4 kinase. For eNOS mRNA detection, RNase protection assays were performed by using the RNase Protection Assay III kit from Ambion, Austin, TX, according to the manufacturer's instructions. Five to 20 μg of total RNA was used per reaction. Cyclophilin antisense control template was obtained from Ambion and labeled using T7 RNA polymerase. Primer sequences for RT-PCRs were as follows: eNOS, 5′-CGAACAGCGGCTTCAAGAGGTG-3′ and 5′-CTGGATCCGGCCCACGCAGCG-3′; β-actin, 5′-AAAGACCTGTACGCCAACAC-3′ and 5′-GTCATACTCCTGCTTGCTGAT-3′. The protocol for quantitative real-time RT-PCR was the same as described previously (17Zhang J. Jin X. Fang S. Wang R. Li Y. Wang N. Guo W. Wang Y. Wen D. Wei L. Dong Z. Kuang G. Carcinogenesis. 2005; 26: 1748-1753Crossref PubMed Scopus (107) Google Scholar). Luciferase Assay—For luciferase assay, the cultured cells were washed in phosphate-buffered saline, resuspended in 300 μl of cold cell lysis buffer (Promega), and lysed by vortexing with acid-washed glass beads (Sigma). One microliter of a 1:50 dilution of the lysate was added to 100 μl of luciferase assay regent (Promega), and luciferase activity was detected with a luminometer (TD-20/20 Turner Designs). Protein concentrations of crude lysates were determined by the Bradford method (Bio-Rad) and used to normalize activity values. Western Blot—Proteins extracted from the cultured cells were separated by 10% SDS-PAGE and transferred to nitrocellulose membranes. The membrane was blocked in 5% nonfat milk in TBS-T (50 mmol/liter Tris, pH 7.5, 150 mmol/liter NaCl, 0.05% Tween 20) for 1 h at room temperature. After incubation with primary antibodies in TBS-T containing 5% milk overnight at 4 °C, the membrane was washed extensively with TBS-T before incubation with secondary anti-rabbit horseradish peroxidase-conjugated antibody for 1 h at room temperature. After extensive washing with TBS-T, the membrane was visualized with ECL plus reagents for chemiluminescence detection (Amersham Biosciences). Statistic Analyses—All quantitative data were presented as the mean ± S.E. of three separate experiments and compared by Student’s t test for between group differences. The p < 0.05 was regarded as statistically significant. Association between the Expressions of the 27-nt sir-RNA and eNOS—Because 27nt sir-RNA is likely derived from the eNOS gene, we first evaluated the possible relationship in the expression between the two. Among the HUVECs collected from different individuals (10Senthil D. Raveendran M. Shen Y.H. Utama B. Dudley D. Wang J. Wang X.L. DNA Cell Biol. 2005; 24: 218-224Crossref PubMed Scopus (59) Google Scholar), we selected HUVECs with the confirmed 5 × 27-nt repeat homozygotes (n = 3) or 4 × 27-nt repeat homozygotes (n = 3) defined by PCR genotyping described earlier (10Senthil D. Raveendran M. Shen Y.H. Utama B. Dudley D. Wang J. Wang X.L. DNA Cell Biol. 2005; 24: 218-224Crossref PubMed Scopus (59) Google Scholar). We cultured these cells to full confluence. Total RNA and proteins were isolated from the cultured cells. Expression of 27nt sir-RNA was analyzed by Northern blot; expression of eNOS was measured by the quantitative real-time RT-PCR for mRNA and Western blot for the protein levels. As shown in Fig. 1A, HUVECs with 5 × 27-nt repeats had higher 27nt sir-RNA levels than those with 4 × 27-nt repeats (49.8 ± 3.9 versus 39.6 ± 1.6, p < 0.05). However, the levels of eNOS protein (Fig. 1B) and mRNA (Fig. 1C) were significantly reduced in HUVECs with 5 × 27-nt repeats than those with 4 × 27-nt repeats (eNOS protein: 26.1 ± 0.1 versus 40.5 ± 0.8, p < 0.05). Tissue-specific Expression of the 27nt sir-RNA—To explore the cell-specific expression in the 27nt sir-RNA, we isolated or purchased total RNA from 12 different types of human cells or tissues. We measured the 27nt sir-RNA and eNOS mRNA using Northern blot. As shown in Fig. 2, the 27nt sir-RNA was only detectable in HAECs, which corresponded with the expression of eNOS mRNA. Expression of the 27nt sir-RNA by the eNOS cDNA-Intron 4 Constructs—Because the 27nt sir-RNA is co-expressed with the eNOS, we designed experiments to investigate the mechanisms responsible for 27nt sir-RNA biogenesis. We generated three constructs as outlined in Fig. 3A. These constructs were built based on the pCMV-2B-eNOS full-length cDNA plasmid generated in our laboratory (18Gan Y. Shen Y.H. Wang J. Wang X. Utama B. Wang X.L. J. Biol. Chem. 2005; 280: 16467-16475Abstract Full Text Full Text PDF PubMed Scopus (87) Google Scholar, 19Gan Y. Shen Y.H. Utama B. Wang J. Coselli J. Wang X.L. Biochem. Biophys. Res. Commun. 2006; 340: 29-34Crossref PubMed Scopus (18) Google Scholar). In Vector 1, the DNA fragment containing the entire intron 4 sequence was inserted. To not disrupt the eNOS coding cDNA, we selected the ScaI site and the insert contained the sequence from part of exon 3 to the entire intron 4 (4674 to 6498 bp) with the ScaI adaptor added at both ends. The vectors with correct sequence and orientation determined by the direct sequencing were selected for the study. Intron 4 spans from 5006 to 6498 bp; the 5 × 27-nt repeat containing the region starts at 5331 to 5446 bp. Vector 2 contained only a part of intron 4 (5130 to 6430 bp), which includes 5 × 27-nt repeats but with intron 4 splicing junctions at 5′ and 3′ ends being removed. Vector 3 had no eNOS cDNA but has the cloned segment of 4674 to 6498 bp inserted at the 3′ end of the vector CMV promoter. All three constructs were then transfected into HeLa cells. We chose HeLa as the host cells because they have the necessary eNOS expression machineries but without endogenous 27nt sir-RNA (11Zhang M.X. Ou H. Shen Y.H. Wang J. Coselli J. Wang X.L. Proc. Natl. Acad. Sci. U. S. A. 2005; 102: 16967-16972Crossref PubMed Scopus (107) Google Scholar, 12Ou H. Shen Y.H. Utama B. Wang J. Wang X. Coselli J. Wang X.L. Arterioscler. Thromb. Vasc. Biol. 2005; 25: 2509-2514Crossref PubMed Scopus (31) Google Scholar). Total RNA was extracted 48 h after transfection; 27nt sir-RNA was measured by Northern blot using 32P-labeled 27-nt oligonucleotide probe. As shown in Fig. 3B, only Vector 1, which contains the full-length eNOS cDNA and complete intron 4 with 5′ and 3′ splicing junctions intact, produced the 27nt sir-RNA similarly as the HAECs. Removal of splicing junctions in Vector 2 abolished the 27nt sir-RNA biogenesis. This suggests that a splicing process similar to eNOS pre-mRNA splicing may be required for the 27nt sir-RNA biogenesis. Lack of 27nt sir-RNA production in Vector 3 indicates that DNA sequences up to exon 3 upstream of 27-nt repeats are not sufficient to drive the expression of the 27nt sir-RNA. To further evaluate the relationship between the numbers of the 27-nt repeats and the 27nt sir-RNA biogenesis, we generated the pCMV-eNOS cDNA-intron 4 construct containing 10 × 27-nt repeats based on the design of Vector 1. We transfected the vectors containing either 5 × 27- or 10 × 27-nt repeats into HeLa cells and HAEC total RNA and the protein were extracted 48 h post-transfection. Fig. 3C (upper panel) shows the 27nt sir-RNA in transfection HeLa cells by Northern blot. The 10 × 27-nt repeat construct produced significantly more 27nt sir-RNA (70.3 ± 0.5) than those of the 5 × 27-nt construct (32.9 ± 2.8, p < 0.05). To investigate whether the overexpressed 27-nt RNA suppressed the host cell eNOS expression, we further transfected these two vectors to HAECs. The eNOS expression by Western blot in HAECs transfected with the 10 × 27-nt construct had significantly lower eNOS protein than those transfected with the 5 × 27-nt construct (eNOS protein: 9.6 ± 0.2 versus 80.3 ± 0.4, p < 0.01). Role of eNOS Pre-mRNA Splicing in 27nt sir-RNA Biogenesis—Because deletion analysis showed that splicing junctions of intron 4 were essential for the 27nt sir-RNA biogenesis, we further investigated the role of eNOS pre-mRNA splicing in 27nt sir-RNA production by mutating the nucleotides in the splicing junctions. Fig. 4 shows the schematic design of the mutagenesis at the 5′ end GCGA|GTGC and 3′ end GCTCAG|GT splice junctions of the eNOS intron 4. Vector 1 as described in the legend to Fig. 3 was used as the template for mutagenesis. We designed two pairs of specific mutation primers to introduce a mutation at the 5′ end from GT to AT, and at the 3′ end from AG to CG. Vector-a is the wild-type control; Vector-b contains a mutation at the 5′ end; Vector-c contains a mutation at the 3′ end; Vector-d contains mutations at both 5′ and 3′ ends. Forty-eight hours after transfection of these constructs to the HeLa cells, total RNA was extracted for 27nt sir-RNA detection. As shown in Fig. 4, mutations at either splicing junction of intron 4 abolished the biogenesis of the 27nt sir-RNA, and caused accumulation of specific pre-sir-RNA sized ∼150 nt. Possibility of an Independent Promoter Drives 27nt sir-RNA Expression—To study the possibility that an independent promoter may be responsible for the expression of 27nt sir-RNA, we first prepared serial deletion reporter constructs by cloning the 5′-flanking sequence 1.5-kb upstream of the 27-nt repeats at eNOS intron 4 into the luciferase reporter vectors (Fig. 5A), which were then transfected to HeLa cells. At 48 h post-transfection, we measured luciferase activity and luciferase mRNA levels. Our experiment showed no promoter activity of this region. To investigate the possibility that the luciferase reporter vector coding regions for transcription and translation may not be suitable to study the function of the promoter that drives the small RNA expression, we further cloned 766 bp upstream of the 27-nt repeats together with the entire eNOS intron 4 into the pGL3-basic vector at the KpnI and XhoI sites (Fig. 5B). As shown in Fig. 5B, the construct produced no 27nt sir-RNA, which suggests no independent promoter exists for the 27nt sir-RNA biogenesis, at least not within the 766-bp upstream region. Relevance of MicroRNA Processing Machinery in the 27nt sir-RNA Biogenesis—We next examined the relevance of common processing machineries for small RNAs in the 27nt sir-RNA biogenesis. It has generally been assumed that RNase type III Drosha is responsible for the nuclear small RNA, particularly miRNA, process to produce precursor miRNA. Pre-miRNAs are then exported to the cytoplasm by exportin 5 and processed into miRNA duplexes through the action of the cytoplasmic type III RNase Dicer. To study whether Dicer or Drosha is also involved in 27nt sir-RNA processing, we suppressed the expression of Dicer or Drosha by transfecting Drosha- or Dicer-specific siRNA to HAECs (Fig. 6A). Total RNA was extracted 48 h after transfection and subjected to Northern blot for 27nt sir-RNA detection. We showed that repression of Drosha or Dicer resulted in significant reduction in the 27nt sir-RNA expression (Fig. 6B). The reduced 27nt sir-RNA corresponded with increased host gene eNOS expression (Fig. 6C). In the same RNA extracts, which were extracted 24 h after the respective Drosha- or Dicer-specific siRNA treatment, we also found that whereas the Dicer or Drosha knockdown reduced the expression of 27nt sir-RNA, the 27-nt specific pre-sir-RNA was accumulated (Fig. 6D). Although we have attempted to classify this intronic repeat-derived small RNA as a miRNA (11Zhang M.X. Ou H. Shen Y.H. Wang J. Coselli J. Wang X.L. Proc. Natl. Acad. Sci. U. S. A. 2005; 102: 16967-16972Crossref PubMed Scopus (107) Google Scholar), most features in biogenesis, processing, and possible mechanisms of effects on target genes do not meet the criteria as a classical miRNA. Our current study suggests that 27nt sir-RNA is derived from the 27-nt repeat sequence in eNOS intron 4 through the eNOS pre-mRNA splicing. The more the number of 27-nt repeats, the more the 27nt sir-RNA is produced. This association is biologically significant because the number of 27-nt repeats in eNOS intron 4 is reported to be associated with risk of myocardial infarction, especially in smokers (20Wang X.L. Sim A.S. Badenhop R.F. McCredie R.M. Wilcken D.E. Nat. Med. 1996; 2: 41-45Crossref PubMed Scopus (547) Google Scholar). We further discovered that nuclear actin tended to bind to the 27-nt repeat element and partially attenuate the 27-nt RNA-mediated eNOS suppression (12Ou H. Shen Y.H. Utama B. Wang J. Wang X. Coselli J. Wang X.L. Arterioscler. Thromb. Vasc. Biol. 2005; 25: 2509-2514Crossref PubMed Scopus (31) Google Scholar). Currently, several types of small RNAs have been described: miRNA, piwiRNA (21Aravin A. Gaidatzis D. Pfeffer S. Lagos-Quintana M. Landgraf P. Iovino N. Morris P. Brownstein M.J. Kuramochi-Miyagawa S. Nakano T. Chien M. Russo J.J. Ju J. Sheridan R. Sander C. Zavolan M. Tuschl T. Nature. 2006; 442: 203-207Crossref PubMed Scopus (1141) Google Scholar), siRNA, tiny noncoding RNA, heterochromatic siRNAs, and repeat-associated small RNAs in plants and animals (22Ambros V. Lee R.C. Lavanway A. Williams P.T. Jewell D. Curr. Biol. 2003; 13: 807-818Abstract Full Text Full Text PDF PubMed Scopus (570) Google Scholar, 23Aravin A.A. Lagos-Quintana M. Yalcin A. Zavolan M. Marks D. Snyder B. Gaasterland T. Meyer J. Tuschl T. Dev. Cell. 2003; 5: 337-350Abstract Full Text Full Text PDF PubMed Scopus (748) Google Scholar). Some of these small RNAs could be present only during the developmental stage or be responsible for tissue-specific expressions (23Aravin A.A. Lagos-Quintana M. Yalcin A. Zavolan M. Marks D. Snyder B. Gaasterland T. Meyer J. Tuschl T. Dev. Cell. 2003; 5: 337-350Abstract Full Text Full Text PDF PubMed Scopus (748) Google Scholar). These small RNAs typically are ∼21-25 nt in length; longer ones are mostly from repeat-associated small RNAs (23Aravin A.A. Lagos-Quintana M. Yalcin A. Zavolan M. Marks D. Snyder B. Gaasterland T. Meyer J. Tuschl T. Dev. Cell. 2003; 5: 337-350Abstract Full Text Full Text PDF PubMed Scopus (748) Google Scholar). Although siRNAs are typically from an exogenous source or during virus infection, miRNAs are mainly transcribed through designated genomic sequences (24Cullen B.R. Virus Res. 2004; 102: 3-9Crossref PubMed Scopus (76) Google Scholar). In some cases, the miRNAs can also be derived from transcribed introns spliced during the nuclear pre-mRNA process (14Zeng Y. Oncogene. 2006; 25: 6156-6162Crossref PubMed Scopus (229) Google Scholar, 25Kim Y.K. Kim V.N. EMBO J. 2007; 26: 775-783Crossref PubMed Scopus (611) Google Scholar). There is a clear definition for what qualifies as miRNA, which is a distinct ∼22-nt RNA transcript detected by Northern blot. Biogenesis criteria include existence of 50-80-nt pre-miRNA stem-loops to be processed by the Microprocessor complex of nucleases and associated factors, including the RNase III Drosha and its partner DGCR8/Pasha within the nucleus (26Zeng Y. Cullen B.R. Methods Mol. Biol. 2006; 342: 49-56PubMed Google Scholar). Through exportin-5, the pre-miRNAs are exported to the cytoplasm and processed by Dicer to become mature miRNAs, which will stay in the cytoplasm to either induce target mRNA degradation or directly inhibit translation (24Cullen B.R. Virus Res. 2004; 102: 3-9Crossref PubMed Scopus (76) Google Scholar). Contrary to siRNA, which requires a perfect sequence match and initiates gene-specific inhibition, miRNA does not require a perfect match of the target mRNA and can regulate more than 200 target mRNAs (27Rajewsky N. Nat. Genet. 2006; 38: S8-S13Crossref PubMed Scopus (939) Google Scholar). A recent description of intronic microRNA pre-miRNAs (mirtrons) was reported (28Ruby J.G. Jan C.H. Bartel D.P. Nature. 2007; 448: 83-86Crossref PubMed Scopus (1139) Google Scholar, 29Berezikov E. Chung W.J. Willis J. Cuppen E. Lai E.C. Mol. Cell. 2007; 28: 328-336Abstract Full Text Full Text PDF PubMed Scopus (583) Google Scholar), which bears the closest resemblance to the sir-RNA we discovered. Unlike the classical miRNA, the biogenesis of mirtrons is processed without the involvement of Drosha-mediated cleavage. Nevertheless, our 27-nt small RNA has the following biological features, which are somehow distinct from most existing small RNAs. They include the exclusive nuclear presence of the 27nt sir-RNA, which is derived from the intronic repeat sequence (11Zhang M.X. Ou H. Shen Y.H. Wang J. Coselli J. Wang X.L. Proc. Natl. Acad. Sci. U. S. A. 2005; 102: 16967-16972Crossref PubMed Scopus (107) Google Scholar, 12Ou H. Shen Y.H. Utama B. Wang J. Wang X. Coselli J. Wang X.L. Arterioscler. Thromb. Vasc. Biol. 2005; 25: 2509-2514Crossref PubMed Scopus (31) Google Scholar). It appears only specifically inhibiting the host eNOS gene rather than several hundred unrelated genes (11Zhang M.X. Ou H. Shen Y.H. Wang J. Coselli J. Wang X.L. Proc. Natl. Acad. Sci. U. S. A. 2005; 102: 16967-16972Crossref PubMed Scopus (107) Google Scholar). The regulatory target stays within the nucleus by regulating eNOS gene transcription or pre-mRNA splicing directly. Using the RNA mfold web server, several stem-loop structures can be modeled with the 5 × 27-nt repeat sequence. Fig. 7 shows two examples of the modeling by including only the 27-nt repeat sequence. However, it is not clear how multiple copies of the 27-nt RNA can be cleaved from the repeat sequence of the single stem-loop structure. Our experiments have clearly shown that the number of 27-nt repeats is linearly associated with the amount of 27nt sir-RNA. These biological features suggest that our 27-nt small RNA is either a new class of small RNA, i.e. sir-RNA, or an atypical form of the existing miRNA or mirtrons. However, the fact that Dicer suppression led to decreased 27nt sir-RNA expression suggests that the cytoplasmic process may also be involved. This finding is somewhat inconsistent with the fact of the exclusive nuclear presence of the 27nt sir-RNA. It is possible that the effect of Dicer suppression on the 27nt sir-RNA is an indirect one. It is also possible that protein knockdown did not translate to functional knockdown in which the observed findings are not direct relationships between Drosha and 27nt sir-RNA or Dicer and 27nt sir-RNA. Alternatively, the 27nt sir-RNA biogenesis indeed involves a cytoplasmic process although this appears to be biologically redundant because the 27nt sir-RNA is derived from the nucleus and functions within the nucleus. One of the underlying assumptions in our experiments is that the sequence of the 27-nt sir-RNA is unique and exactly equivalent to the 27-nt intron 4 repeat sequence. However, this may not be exactly correct. The observed 27nt sir-RNA may be a family of closely related sequences. More experiments are clearly needed to resolve these issues. With the genome-wide existence of similar short intronic repeat sequence (30Bennett E.A. Coleman L.E. Tsui C. Pittard W.S. Devine S.E. Genetics. 2004; 168: 933-951Crossref PubMed Scopus (128) Google Scholar, 31Lander E.S. Linton L.M. Birren B. Nusbaum C. Zody M.C. Baldwin J. Devon K. Dewar K. Doyle M. FitzHugh W. Funke R. Gage D. Harris K. Heaford A. Howland J. Kann L. Lehoczky J. LeVine R. McEwan P. McKernan K. Meldrim J. Mesirov J.P. Miranda C. Morris W. Naylor J. Raymond C. Rosetti M. Santos R. Sheridan A. Sougnez C. Stange-Thomann N. Stojanovic N. Subramanian A. Wyman D. Rogers J. Sulston J. Ainscough R. Beck S. Bentley D. Burton J. Clee C. Carter N. Coulson A. Deadman R. Deloukas P. Dunham A. Dunham I. Durbin R. French L. Grafham D. Gregory S. Hubbard T. Humphray S. Hunt A. Jones M. Lloyd C. McMurray A. Matthews L. Mercer S. Milne S. Mullikin J.C. Mungall A. Plumb R. Ross M. Shownkeen R. Sims S. Waterston R.H. Wilson R.K. Hillier L.W. McPherson J.D. Marra M.A. Mardis E.R. Fulton L.A. Chinwalla A.T. Pepin K.H. Gish W.R. Chissoe S.L. Wendl M.C. Delehaunty K.D. Miner T.L. Delehaunty A. Kramer J.B. Cook L.L. Fulton R.S. Johnson D.L. Minx P.J. Clifton S.W. Hawkins T. Branscomb E. Predki P. Richardson P. Wenning S. Slezak T. Doggett N. Cheng J.F. Olsen A. Lucas S. Elkin C. Uberbacher E. Frazier M. Gibbs R.A. Muzny D.M. Scherer S.E. Bouck J.B. Sodergren E.J. Worley K.C. Rives C.M. Gorrell J.H. Metzker M.L. Naylor S.L. Kucherlapati R.S. Nelson D.L. Weinstock G.M. Sakaki Y. Fujiyama A. Hattori M. Yada T. Toyoda A. Itoh T. Kawagoe C. Watanabe H. Totoki Y. Taylor T. Weissenbach J. Heilig R. Saurin W. Artiguenave F. Brottier P. Bruls T. Pelletier E. Robert C. Wincker P. Smith D.R. Doucette-Stamm L. Rubenfield M. Weinstock K. Lee H.M. Dubois J. Rosenthal A. Platzer M. Nyakatura G. Taudien S. Rump A. Yang H. Yu J. Wang J. Huang G. Gu J. Hood L. Rowen L. Madan A. Qin S. Davis R.W. Federspiel N.A. Abola A.P. Proctor M.J. Myers R.M. Schmutz J. Dickson M. Grimwood J. Cox D.R. Olson M.V. Kaul R. Shimizu N. Kawasaki K. Minoshima S. Evans G.A. Athanasiou M. Schultz R. Roe B.A. Chen F. Pan H. Ramser J. Lehrach H. Reinhardt R. McCombie W.R. de la Bastide M. Dedhia N. Blocker H. Hornischer K. Nordsiek G. Agarwala R. Aravind L. Bailey J.A. Bateman A. Batzoglou S. Birney E. Bork P. Brown D.G. Burge C.B. Cerutti L. Chen H.C. Church D. Clamp M. Copley R.R. Doerks T. Eddy S.R. Eichler E.E. Furey T.S. Galagan J. Gilbert J.G. Harmon C. Hayashizaki Y. Haussler D. Hermjakob H. Hokamp K. Jang W. Johnson L.S. Jones T.A. Kasif S. Kaspryzk A. Kennedy S. Kent W.J. Kitts P. Koonin E.V. Korf I. Kulp D. Lancet D. Lowe T.M. McLysaght A. Mikkelsen T. Moran J.V. Mulder N. Pollara V.J. Ponting C.P. Schuler G. Schultz J. Slater G. Smit A.F. Stupka E. Szustakowski J. Thierry-Mieg D. Thierry-Mieg J. Wagner L. Wallis J. Wheeler R. Williams A. Wolf Y.I. Wolfe K.H. Yang S.P. Yeh R.F. Collins F. Guyer M.S. Peterson J. Felsenfeld A. Wetterstrand K.A. Patrinos A. Morgan M.J. de Jong P. Catanese J.J. Osoegawa K. Shizuya H. Choi S. Chen Y.J. Nature. 2001; 409: 860-921Crossref PubMed Scopus (17820) Google Scholar), we predict that this class of small RNA may function as a gene-specific negative feedback regulator. With varying numbers of the repeats between individuals, the sir-RNA based regulation could be responsible for individual differences in phenotypic expression, hence disease susceptibility. The more the host gene is transcribed, the more gene-specific sir-RNA will be produced, which forms a negative feedback regulatory loop to fine-tune the host gene expression. Variable numbers of the polymorphic repeats in populations will be responsible for quantitative individual differences in the expressed genes. More specifically, the 27-nt repeats in eNOS intron 4 can be converted to 27nt sir-RNA and functions as a negative feedback regulator of eNOS expression. Individuals with different numbers of 27-nt repeats will have different levels of 27nt sir-RNA, which is responsible for individual differences in eNOS expression, hence susceptibility to vascular diseases." @default.
• W2048484328 created "2016-06-24" @default.
• W2048484328 creator A5004353294 @default.
• W2048484328 creator A5011477558 @default.
• W2048484328 creator A5022675390 @default.
• W2048484328 creator A5032764121 @default.
• W2048484328 creator A5052152398 @default.
• W2048484328 creator A5071421730 @default.
• W2048484328 creator A5075596275 @default.
• W2048484328 creator A5090374198 @default.
• W2048484328 date "2008-05-01" @default.
• W2048484328 modified "2023-10-17" @default.
• W2048484328 title "Biogenesis of Short Intronic Repeat 27-Nucleotide Small RNA from Endothelial Nitric-oxide Synthase Gene" @default.
• W2048484328 cites W144423133 @default.
• W2048484328 cites W1657916452 @default.
• W2048484328 cites W1821918060 @default.
• W2048484328 cites W1987595401 @default.
• W2048484328 cites W2009326616 @default.
• W2048484328 cites W2014946489 @default.
• W2048484328 cites W2021449905 @default.
• W2048484328 cites W2035620169 @default.
• W2048484328 cites W2035930185 @default.
• W2048484328 cites W2037141750 @default.
• W2048484328 cites W2041992860 @default.
• W2048484328 cites W2066839769 @default.
• W2048484328 cites W2068411944 @default.
• W2048484328 cites W2072155079 @default.
• W2048484328 cites W2076795933 @default.
• W2048484328 cites W2083977776 @default.
• W2048484328 cites W2108923962 @default.
• W2048484328 cites W2111650823 @default.
• W2048484328 cites W2114887001 @default.
• W2048484328 cites W2120127537 @default.
• W2048484328 cites W2131475898 @default.
• W2048484328 cites W2138043022 @default.
• W2048484328 cites W2139996974 @default.
• W2048484328 cites W2150616706 @default.
• W2048484328 cites W2151911276 @default.
• W2048484328 cites W2155396586 @default.
• W2048484328 cites W2161017601 @default.
• W2048484328 cites W2168909179 @default.
• W2048484328 cites W4255861600 @default.
• W2048484328 doi "https://doi.org/10.1074/jbc.m801933200" @default.
• W2048484328 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2386909" @default.
• W2048484328 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18390539" @default.
• W2048484328 hasPublicationYear "2008" @default.
• W2048484328 type Work @default.
• W2048484328 sameAs 2048484328 @default.
• W2048484328 citedByCount "57" @default.
• W2048484328 countsByYear W20484843282012 @default.
• W2048484328 countsByYear W20484843282013 @default.
• W2048484328 countsByYear W20484843282014 @default.
• W2048484328 countsByYear W20484843282015 @default.
• W2048484328 countsByYear W20484843282016 @default.
• W2048484328 countsByYear W20484843282017 @default.
• W2048484328 countsByYear W20484843282018 @default.
• W2048484328 countsByYear W20484843282019 @default.
• W2048484328 countsByYear W20484843282020 @default.
• W2048484328 countsByYear W20484843282021 @default.
• W2048484328 countsByYear W20484843282022 @default.
• W2048484328 crossrefType "journal-article" @default.
• W2048484328 hasAuthorship W2048484328A5004353294 @default.
• W2048484328 hasAuthorship W2048484328A5011477558 @default.
• W2048484328 hasAuthorship W2048484328A5022675390 @default.
• W2048484328 hasAuthorship W2048484328A5032764121 @default.
• W2048484328 hasAuthorship W2048484328A5052152398 @default.
• W2048484328 hasAuthorship W2048484328A5071421730 @default.
• W2048484328 hasAuthorship W2048484328A5075596275 @default.
• W2048484328 hasAuthorship W2048484328A5090374198 @default.
• W2048484328 hasBestOaLocation W20484843281 @default.
• W2048484328 hasConcept C104317684 @default.
• W2048484328 hasConcept C112243037 @default.
• W2048484328 hasConcept C131934819 @default.
• W2048484328 hasConcept C153911025 @default.
• W2048484328 hasConcept C181199279 @default.
• W2048484328 hasConcept C185592680 @default.
• W2048484328 hasConcept C2777622882 @default.
• W2048484328 hasConcept C2778326061 @default.
• W2048484328 hasConcept C2992676626 @default.
• W2048484328 hasConcept C512185932 @default.
• W2048484328 hasConcept C54355233 @default.
• W2048484328 hasConcept C55493867 @default.
• W2048484328 hasConcept C67705224 @default.
• W2048484328 hasConcept C86803240 @default.
• W2048484328 hasConcept C94671646 @default.
• W2048484328 hasConcept C95444343 @default.
• W2048484328 hasConceptScore W2048484328C104317684 @default.
• W2048484328 hasConceptScore W2048484328C112243037 @default.
• W2048484328 hasConceptScore W2048484328C131934819 @default.
• W2048484328 hasConceptScore W2048484328C153911025 @default.
• W2048484328 hasConceptScore W2048484328C181199279 @default.
• W2048484328 hasConceptScore W2048484328C185592680 @default.
• W2048484328 hasConceptScore W2048484328C2777622882 @default.
• W2048484328 hasConceptScore W2048484328C2778326061 @default.
• W2048484328 hasConceptScore W2048484328C2992676626 @default.
• W2048484328 hasConceptScore W2048484328C512185932 @default.
• W2048484328 hasConceptScore W2048484328C54355233 @default.
• W2048484328 hasConceptScore W2048484328C55493867 @default.

• next